May 24, 2017 / 10:35 AM / 2 years ago

WuXi Biologics to launch $513 mln Hong Kong IPO on Thursday -IFR

HONG KONG, May 24 (Reuters) - WuXi Biologics (Cayman) Inc, a Chinese contract drug research and development company, plans to launch on Thursday an initial public offering of up to $513 million in Hong Kong, IFR reported, citing people close to the deal.

The company is offering 193 million shares in an indicative range of HK$18.60 to HK$20.60 each, valuing the total deal at up to HK$3.98 billion, the Thomson Reuters publication added.

WuXi Biologics, which does work for pharmaceutical and biotechnology firms, did not immediately respond to a Reuters request for comment.

Bank of America Merrill Lynch, China Merchants Securities and Morgan Stanley are joint sponsors of the IPO, the listing prospectus shows. ($1=7.7891 Hong Kong dollars) (Reporting by Fiona Lau of IFR; Writing by Elzio Barreto; Editing by Clarence Fernandez)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below